The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Gain Therapeutics Inc shares valued at $115,770 were purchased by Riley Jeffrey Scott on Mar 28 ’24. At $3.86 per share, Riley Jeffrey Scott acquired 30,000 shares. The insider’s holdings grew to 30,000 shares worth approximately $39000.0 following the completion of this transaction.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Also, Alder Matthias sold 206 shares, netting a total of over 507 in proceeds. Following the sale of shares at $2.46 each, the insider now holds 5,286 shares.
Before that, Alder Matthias had sold 1,820 shares from its account. In a trade valued at $4,550, the Chief Executive Officer traded Gain Therapeutics Inc shares for $2.50 each. Upon closing the transaction, the insider’s holdings decreased to 1,820 shares, worth approximately $6311.5.
As published in their initiating research note from Oppenheimer on April 12, 2021, Gain Therapeutics Inc [GANX] has been an Outperform and the price target has been revised to $30. Analysts at BTIG Research started covering the stock with ‘”a Buy”‘ outlook in a report released in mid April.
Analyzing GANX Stock Performance
During the last five days, there has been a drop of approximately -38.39%. Over the course of the year, Gain Therapeutics Inc shares have dropped approximately -60.18%. Shares of the company reached a 52-week high of $5.3300 on 02/07/24 and a 52-week low of $1.2000 on 06/20/24. A 50-day SMA is recorded $2.6042, while a 200-day SMA reached $3.2448. Nevertheless, trading volume fell to 0.56 million shares from 0.46 million shares the previous day.
Support And Resistance Levels for Gain Therapeutics Inc (GANX)
According to the 24-hour chart, there is a support level at 1.2333, which, if violated, would cause prices to drop to 1.1667. In the upper region, resistance lies at 1.3333. The next price resistance is at 1.3667. RSI (Relative Strength Index) is 25.69 on the 14-day chart, showing oversold technical sentiment. Moving Average Convergence Divergence (MACD) is at -0.7121, which suggests the price will decrease in the coming days. Percent R is at 93.33%, indicating bearish price movement. Stochastics %K at buying indicates that the stock is to be held.
